FPRX - Five Prime Therapeutics Stock Price, News & Analysis

$26.97 -0.02 (-0.07 %)
(As of 11/23/2017 03:21 PM ET)
Previous Close$26.99
Today's Range$26.86 - $27.61
52-Week Range$21.41 - $60.98
Volume329,000 shs
Average Volume405,817 shs
Market Capitalization$780.25 million
P/E RatioN/A
Dividend YieldN/A
Beta4.18

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:FPRX
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio7.29%
Quick Ratio7.29%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.69 million
Price / Sales25.42
Cash FlowN/A
Price / CashN/A
Book Value$9.89 per share
Price / Book2.73

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($5.07)
Net Income$-65,690,000.00
Net Margins-408.42%
Return on Equity-41.57%
Return on Assets-35.39%

Miscellaneous

Employees195
Outstanding Shares28,930,000

Frequently Asked Questions for Five Prime Therapeutics (NASDAQ:FPRX)

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($1.55) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.35) by $0.19. The biotechnology company had revenue of $8.33 million for the quarter, compared to analyst estimates of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.72) EPS. View Five Prime Therapeutics' Earnings History.

Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?

6 analysts have issued 12 month target prices for Five Prime Therapeutics' stock. Their forecasts range from $50.00 to $94.00. On average, they anticipate Five Prime Therapeutics' share price to reach $67.75 in the next twelve months. View Analyst Ratings for Five Prime Therapeutics.

What are Wall Street analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

  • 1. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (11/9/2017)
  • 2. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
  • 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
  • 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)

Who are some of Five Prime Therapeutics' key competitors?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:

  • Lewis T. Williams M.D. Ph.D., Executive Chairman of the Board (Age 67)
  • Marc L. Belsky, Chief Financial Officer, Senior Vice President (Age 61)
  • Aron Marc Knickerbocker MBA, President, Chief Executive Officer, Chief Operating Officer, Director (Age 47)
  • Kevin Baker Ph.D., Senior Vice President, Development Sciences (Age 56)
  • Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer (Age 54)
  • Francis Willard Sarena J.D., Chief Strategy Officer and Secretary (Age 46)
  • Mark D. McDade, Lead Independent Director (Age 61)
  • Garry Nicholson, Director
  • Franklin M. Berger, Independent Director (Age 67)
  • Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)

Who owns Five Prime Therapeutics stock?

Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.01%), Victory Capital Management Inc. (1.90%), Pictet Asset Management Ltd. (1.67%), JPMorgan Chase & Co. (0.99%), Bank of New York Mellon Corp (0.78%) and Wells Fargo & Company MN (0.64%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Artal Group S.A., Vident Investment Advisory LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, JPMorgan Chase & Co., Virginia Retirement Systems ET AL and Candriam Luxembourg S.C.A.. Company insiders that have sold Five Prime Therapeutics company stock in the last year include Francis Willard Sarena, Lewis T Williams and William R Ringo. View Insider Buying and Selling for Five Prime Therapeutics.

Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Point72 Asset Management L.P., Crestline Management LP, Sphera Funds Management LTD., Schwab Charles Investment Management Inc., Schroder Investment Management Group, Platinum Investment Management Ltd. and Granite Point Capital Management L.P.. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy Five Prime Therapeutics stock?

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of Five Prime Therapeutics stock can currently be purchased for approximately $26.97.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $780.25 million and generates $30.69 million in revenue each year. The biotechnology company earns $-65,690,000.00 in net income (profit) each year or ($5.07) on an earnings per share basis. Five Prime Therapeutics employs 195 workers across the globe.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 2 Corporate Dr, SOUTH SAN FRANCISCO, CA 94080-7047, United States. The biotechnology company can be reached via phone at +1-415-3655600.


MarketBeat Community Rating for Five Prime Therapeutics (FPRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Five Prime Therapeutics (NASDAQ:FPRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $67.75 (151.21% upside)

Consensus Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)

Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017BMO Capital MarketsBoost Price TargetOutperform$71.00 -> $75.00N/AView Rating Details
11/6/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$41.00 -> $50.00N/AView Rating Details
9/12/2017Jefferies Group LLCReiterated RatingBuy$52.00HighView Rating Details
3/24/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$94.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/7/2016Credit Suisse GroupReiterated RatingBuy$54.00N/AView Rating Details
10/25/2016Citigroup Inc.Initiated CoverageBuy$65.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00N/AView Rating Details
5/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$48.00N/AView Rating Details
12/4/2015Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Five Prime Therapeutics (NASDAQ:FPRX)

Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Earnings History by Quarter for Five Prime Therapeutics (NASDAQ FPRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($1.35)($1.55)$16.16 million$8.33 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.15)($1.58)$8.32 million$7.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.96)($1.21)$6.05 million$10.13 millionViewListenView Earnings Details
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.46)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.40)($0.55)$5.39 million$4.65 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.40)($0.33)$5.22 million$6.06 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)$5.39 million$4.98 millionViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)$1.52 million$3.79 millionViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
2017 EPS Consensus Estimate: ($4.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.97)($0.97)($0.97)
Q2 20171($1.03)($1.03)($1.03)
Q3 20172($1.50)($1.34)($1.42)
Q4 20172($1.51)($1.50)($1.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Five Prime Therapeutics (NASDAQ FPRX)

Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 81.90%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ FPRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017William R RingoDirectorSell600$45.33$27,198.00View SEC Filing  
10/2/2017William R RingoDirectorSell1,800$40.26$72,468.00View SEC Filing  
9/28/2017William R RingoDirectorSell2,000$38.00$76,000.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$46.73$23,365.00View SEC Filing  
2/1/2017William R RingoDirectorSell500$46.17$23,085.00View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.04View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.40View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.52View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.00View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Five Prime Therapeutics (NASDAQ FPRX)

Source:
DateHeadline
Five Prime Therapeutics, Inc. (FPRX) Given Average Recommendation of "Hold" by BrokeragesFive Prime Therapeutics, Inc. (FPRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 19 at 5:32 PM
Why This Biotech Still Gets Hit Despite Promising Cancer DataWhy This Biotech Still Gets Hit Despite Promising Cancer Data
finance.yahoo.com - November 13 at 5:52 PM
Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune ...Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune ...
www.nasdaq.com - November 10 at 5:25 PM
Five Prime Therapeutics (FPRX) Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at SITCFive Prime Therapeutics (FPRX) Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at SITC
www.streetinsider.com - November 10 at 5:25 PM
Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual MeetingFive Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
finance.yahoo.com - November 10 at 5:25 PM
Five Prime Therapeutics, Inc. (FPRX) Expected to Announce Quarterly Sales of $9.86 MillionFive Prime Therapeutics, Inc. (FPRX) Expected to Announce Quarterly Sales of $9.86 Million
www.americanbankingnews.com - November 9 at 10:31 AM
Five Prime Therapeutics, Inc. to Post Q4 2017 Earnings of ($1.51) Per Share, Leerink Swann Forecasts (FPRX)Five Prime Therapeutics, Inc. to Post Q4 2017 Earnings of ($1.51) Per Share, Leerink Swann Forecasts (FPRX)
www.americanbankingnews.com - November 9 at 9:56 AM
Five Prime Therapeutics, Inc. (FPRX) Forecasted to Post FY2017 Earnings of ($5.84) Per ShareFive Prime Therapeutics, Inc. (FPRX) Forecasted to Post FY2017 Earnings of ($5.84) Per Share
www.americanbankingnews.com - November 9 at 7:50 AM
Why Five Prime Therapeutics Stock Is on the Rebound TodayWhy Five Prime Therapeutics Stock Is on the Rebound Today
www.fool.com - November 8 at 5:23 PM
Five Prime Announces Third Quarter 2017 Results and Provides Business Update - GlobeNewswire (press release)Five Prime Announces Third Quarter 2017 Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 8 at 7:06 AM
Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data - Business Wire (press release)Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data - Business Wire (press release)
www.businesswire.com - November 8 at 7:06 AM
Five Prime Therapeutics, Inc. (FPRX) Given New $75.00 Price Target at BMO Capital MarketsFive Prime Therapeutics, Inc. (FPRX) Given New $75.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - November 7 at 10:28 PM
Five Prime Therapeutics, Inc. (FPRX) Announces  Earnings ResultsFive Prime Therapeutics, Inc. (FPRX) Announces Earnings Results
www.americanbankingnews.com - November 7 at 12:34 PM
Five Prime Therapeutics (FPRX) CEO Rusty Williams on Q3 2017 Results - Earnings Call TranscriptFive Prime Therapeutics' (FPRX) CEO Rusty Williams on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 4:39 AM
Edited Transcript of FPRX earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of FPRX earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 4:39 AM
BRIEF-Five Prime posts Q3 loss of $1.54 per shareBRIEF-Five Prime posts Q3 loss of $1.54 per share
www.reuters.com - November 6 at 11:38 PM
Five Prime Therapeutics, Inc. 2017 Q3 - Results - Earnings Call SlidesFive Prime Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 6 at 11:38 PM
Five Prime Therapeutics, Inc. (FPRX) Director William R. Ringo Sells 600 SharesFive Prime Therapeutics, Inc. (FPRX) Director William R. Ringo Sells 600 Shares
www.americanbankingnews.com - November 2 at 6:24 PM
Five Prime Therapeutics (FPRX) vs. Intercept Pharmaceuticals (ICPT) Financial ReviewFive Prime Therapeutics (FPRX) vs. Intercept Pharmaceuticals (ICPT) Financial Review
www.americanbankingnews.com - November 2 at 5:30 AM
Five Prime Therapeutics (FPRX) Presents Preclinical Results ... - StreetInsider.comFive Prime Therapeutics (FPRX) Presents Preclinical Results ... - StreetInsider.com
www.streetinsider.com - October 31 at 12:40 AM
Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
finance.yahoo.com - October 30 at 7:39 PM
Five Prime Therapeutics, Inc. (FPRX) Earns Buy Rating from Royal Bank Of CanadaFive Prime Therapeutics, Inc. (FPRX) Earns Buy Rating from Royal Bank Of Canada
www.americanbankingnews.com - October 25 at 10:28 PM
Five Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Buy" from AnalystsFive Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 25 at 7:32 PM
Five Prime Therapeutics (FPRX) Names Aron Knickerbocker to CEO Position; Effective January 1, 2018 - StreetInsider.comFive Prime Therapeutics (FPRX) Names Aron Knickerbocker to CEO Position; Effective January 1, 2018 - StreetInsider.com
www.streetinsider.com - October 23 at 11:37 PM
BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEOBRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO
www.reuters.com - October 23 at 6:34 PM
New chief at Five PrimeNew chief at Five Prime
seekingalpha.com - October 23 at 6:34 PM
Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO ...Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO ...
globenewswire.com - October 23 at 6:33 PM
Five Prime Therapeutics (FPRX) Names Aron Knickerbocker to CEO Position ...Five Prime Therapeutics (FPRX) Names Aron Knickerbocker to CEO Position ...
www.streetinsider.com - October 23 at 6:33 PM
Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018
finance.yahoo.com - October 23 at 6:33 PM
Five Prime Therapeutics, Inc. (FPRX) Expected to Post Quarterly Sales of $9.00 MillionFive Prime Therapeutics, Inc. (FPRX) Expected to Post Quarterly Sales of $9.00 Million
www.americanbankingnews.com - October 21 at 9:50 AM
Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on ... - GlobeNewswire (press release)Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on ... - GlobeNewswire (press release)
globenewswire.com - October 20 at 12:35 AM
Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6 - GlobeNewswire (press release)Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6 - GlobeNewswire (press release)
globenewswire.com - October 20 at 12:35 AM
Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6
finance.yahoo.com - October 19 at 7:34 PM
Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsFive Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 18 at 8:09 PM
ETFs with exposure to Five Prime Therapeutics, Inc. : October 17, 2017ETFs with exposure to Five Prime Therapeutics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 7:29 PM
35 Biggest Movers From Yesterday - Benzinga35 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - October 17 at 5:15 AM
Five Prime Therapeutics, Inc. (FPRX) Upgraded to Buy by Zacks Investment ResearchFive Prime Therapeutics, Inc. (FPRX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM
Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2% - NasdaqFive Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2% - Nasdaq
www.nasdaq.com - October 13 at 4:24 PM
Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%
finance.yahoo.com - October 13 at 4:24 PM
Contrasting Orexigen Therapeutics (OREX) and Five Prime Therapeutics (FPRX)Contrasting Orexigen Therapeutics (OREX) and Five Prime Therapeutics (FPRX)
www.americanbankingnews.com - October 13 at 2:26 PM
Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late ...Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late ...
globenewswire.com - October 12 at 7:39 PM
Five Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral ... - StreetInsider.comFive Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral ... - StreetInsider.com
www.streetinsider.com - October 11 at 4:37 PM
Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingFive Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - October 11 at 4:37 PM
Charting the S&P 500’s break to ‘clear skies’ technical territoryCharting the S&P 500’s break to ‘clear skies’ technical territory
www.marketwatch.com - October 10 at 4:31 PM
ETFs with exposure to Five Prime Therapeutics, Inc. : October 6, 2017ETFs with exposure to Five Prime Therapeutics, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 7:12 PM
Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 6:00 PM
Five Prime Therapeutics, Inc. (FPRX) Director Sells $72,468.00 in StockFive Prime Therapeutics, Inc. (FPRX) Director Sells $72,468.00 in Stock
www.americanbankingnews.com - October 3 at 11:34 PM
William R. Ringo Sells 2,000 Shares of Five Prime Therapeutics, Inc. (FPRX) StockWilliam R. Ringo Sells 2,000 Shares of Five Prime Therapeutics, Inc. (FPRX) Stock
www.americanbankingnews.com - October 2 at 4:34 PM
Five Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Hold" from AnalystsFive Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 30 at 6:36 PM
Five Prime Therapeutics (FPRX) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - SlideshowFive Prime Therapeutics (FPRX) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - Slideshow
seekingalpha.com - September 29 at 2:36 PM

Social Media

Financials

Chart

Five Prime Therapeutics (NASDAQ FPRX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.